Living Donor Kidney TransplantationMuST AKTNCT05459337
Multidisciplinary Support to Access Living Donor Kidney Transplant (MuST AKT)
A study testing MuST AKT in people with Living Donor Kidney Transplantation, run by University of Alberta at 1 site in Canada.
Trial summary
For people living with kidney failure, the two active treatment options are dialysis or kidney transplantation. Transplantation is optimal, and especially from a living donor - offering patients longer survival, a better quality of life, and cost savings for the health system when compared to dialysis. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Living Donor Kidney Transplantation
- What is being tested?
- MuST AKT
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 66 participants
- Where
- 1 siteCanada
- Study dates
- 18 Oct 2022to Sep 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- English speaking
- No obvious contraindication to kidney transplantation
- Successfully completed 'introduction to kidney transplant' module
Who cannot join
- Potential Living Kidney Donor identified
- Previously received organ transplant
- Candidate for multi-organ transplant
- Stanford Integrated Psychosocial Assessment for Transplant (SIPAT) Score >20
- Rapid Estimate of Adult Literacy in Medicine (REALM-66) score <19(illiterate in English)
Trial locations and contacts
1 site in 1 country.
About this study
For people living with kidney failure, the two active treatment options are dialysis or kidney transplantation. Transplantation is optimal, and especially from a living donor - offering patients longer survival, a better quality of life, and cost savings for the health system when compared to dialysis. However, 20% of patients die on dialysis while waiting for a deceased donor organ. As the rate of kidney failure continues to rise, the gap between demand and supply of the organs for transplantation increases.
Compared to other provinces in Canada, the rate of living kidney donor transplantation is lower in Alberta, so it is essential that improvements are made to the process around living kidney donor transplantation, for better patient outcomes and care.
Read more
Our published evidence-based review on strategies to increase living kidney donation, found that for patients with kidney failure, the intervention with the greatest health impact was personalized support, provided by a multidisciplinary team, to inform and educate the patients' social network. A province-wide survey also confirmed that many patients with kidney failure are unable to find a living kidney donor and also find it difficult to approach potential donors due to lack of skills, supports, and resources.
The investigators have developed the Multidisciplinary Support To Access living donor Kidney Transplant (MuST AKT) intervention to support potential kidney transplant recipients find living donors through their social networks, and thereby increase the number of living kidney donor transplants in Alberta. The investigators will test the effectiveness of this intervention.
Read the detailed description
Living donor kidney transplantation (LDKT) is the optimal treatment for end-stage kidney disease patients, offering patients longer survival, a better quality of life, and cost savings for the health system when compared to dialysis. Outcome data shows that only 16% of Canadians on dialysis survive past 10 years, whereas up to 74% of Canadians with a kidney transplant have a functioning kidney after 10 years. The ideal treatment trajectory is to avoid dialysis entirely and receive a living donor transplant prior to dialysis (pre-emptive), which unfortunately only occurs in 10.5% of eligible patients.
Patients with kidney failure report barriers to LDKT, including navigating the system, addressing their concerns and fears, identifying and approaching potential living donors, keeping motivated, and then utilizing the ones unable to donate as advocates. To address these barriers and increase LDKT, the MuST AKT intervention has been developed. MuST AKT is designed to provide personalized support and enable potential kidney transplant recipients to communicate their story and desire for a LDKT with their personal and broader social networks.
A definitive Randomized Controlled Trial is proposed to test the effectiveness of the MuST AKT intervention to increase LDKT outcomes in a larger sample, before scaling to and implementing across Alberta.
Primary Objective:
The primary objective of this study is to examine the effectiveness of the MuST AKT intervention to increase living donor kidney transplantation outcomes.
Hypothesis:
The MuST AKT intervention will increase living donor kidney transplant outcomes compared to the control condition (standard care).
Additional Objectives:
The secondary objective is to evaluate patient outcome improvement by collecting Patient Reported Outcome Measures (PROMs) to assess the proportion of patients who find at least one potential living donor.
The tertiary objective is to evaluate patient experience by collecting i) qualitative interviews and ii) Patient Reported Experience Measures (PREMs) to determine whether this program would be recommended to other patients and to what extent this program helped find a potential living kidney donor.
The quaternary objective is to evaluate the feasibility of this program by assessing consent rate, attendance, adherence, drop-out, intervention fidelity, and cost-effectiveness.
Research Methods/Procedures:
This is a definitive parallel randomized controlled trial with a qualitative interview component. The intervention condition will receive a multidisciplinary, tailored person-centered intervention over three months (MuST AKT program), and the control condition will receive the current standard of care (social worker assessment).
Patients who have been referred for kidney transplantation assessment in Edmonton will be contacted during a standard care kidney transplant education session or over the telephone if the education has been completed. Consenting participants meeting the eligibility requirements will be contacted via telephone by a member of the research team to confirm their enrollment and complete a baseline questionnaire to assess socio-demographics and PREMs. Then participants will be randomized to either the intervention or control condition, using predetermined randomly-generated (by Stata MP 15·1) permuted blocks of 4 and 6. Assignment to condition will be concealed by the database up until the point of assignment. All group and individual sessions will be held either virtually or in-person, at the participants discretion, as long as there are no public health (e.g., COVID-19) restrictions that would prevent in-person visits. If there are public health restrictions that prevent in-person visits, the sessions will be held virtually. Consent rate, attendance, adherence, drop-out, and intervention fidelity will be tracked during enrollment and throughout the duration of the intervention. Upon completion of the intervention (or usual care), participants will complete a post-intervention questionnaire to assess PREMs. Participants in the MuST AKT intervention condition who complete the intervention sessions will be contacted to participate in a semi-structured qualitative interview over the telephone (approximately 45 minutes) within two weeks of their last session. Participants who complete the MuST AKT intervention condition but have not had a potential donor come forward after 12 months of the last session will be contacted to complete a semi-structured interview over the telephone (approximately 20 minutes) to explore factors contributing to their lack of success. Kidney transplant status will be tracked for a period of 24 months post-intervention.
The cost-effectiveness of the intervention will be evaluated after participant data collection is complete (24 months), and values obtained from study records (cost of developing and delivering intervention) and previously published estimates of living donor work-ups and transplantation costs, and cost-savings due to forgoing of alternative therapies (i.e., dialysis).
Intervention Condition: MuST AKT is a multidisciplinary, tailored person-centered intervention aimed to support participants identification of potential donors and communication with their social network. An introductory session will be followed by three sessions (all one-on-one) and a final session 4 with participants family and friends (potential donors and advocates) identified in session 1. The introductory session will be approximately 60 minutes and the remaining intervention sessions will be approximately 90 minutes. Sessions will be facilitated by a trained licensed social worker, a coordinator, or a media expert, with extra training in kidney disease, transplantation, living kidney donation, counselling and interviewing, and patient confidentiality.
Usual care (control condition): In the control condition, participants will go through the current standard of care, which is a social worker assessment. If the intervention is successful in the definitive RCT and approved by Alberta Health Services as the 'new standard of care', people in control condition will be contacted and given the option to participate in the MuST AKT intervention.
Additional Interviews with separate informed consent procedures: Friends and family members of participants taking part in session 4 will be invited to participate in a sub-study, which aims to explore their experiences of group session 4. Those expressing interest will be contacted by a qualitative researcher via telephone, and following informed consent, will participate in a semi-structured interview lasting approximately 20 minutes.
Plan for Data Analysis:
Quantitative: All analyses will be completed in Stata/MP 17.0 (www.stata.com), using an intention-to-treat approach. Fisher's exact tests (for dichotomous outcomes), and t-tests or Wilcoxon rank-sum tests (for continuous outcomes data), will be used as appropriate. Unadjusted proportions, means or medians and their differences along with 95% confidence intervals will be reported. P <0.05 will be considered statistically significant for all quantitative outcomes. Residual, leverage and influence diagnostics will be examined.
Our primary analyses (which includes primary and secondary outcomes) will pool data from both the pilot and the current trials. In secondary analyses, we will generate within trial results to investigate potential heterogeneity of intervention delivery.
Qualitative: Data will be analyzed in NVivo-12 by experienced qualitative researchers independent of the study, using deductive thematic analysis. A coding framework will be established based on the interview guides and updated to include additional themes that emerge from the data. The coding framework will be validated by two coders, any disagreements will be resolved through discussion.
- Conditions
- Living Donor Kidney Transplantation
- Being tested
- MuST AKT
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MuST AKTBehavioural
A behavioural intervention designed to help participants identify and communicate with their social network about living kidney donation.
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Experimental | This arm will receive the MuST AKT intervention, which is a multidisciplinary, tailored person-centered behavioural intervention designed to "help and enable" the potential kidney transplant recipients to achieve what is required to receive a living donor kidney transplantation. Receives: Behavioral: MuST AKT |
| Usual Care (control) | No intervention | In the usual care (control) condition, participants will go through the current standard of care, which is a social worker assessment. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Living Kidney Donor Transplantation
Proportion of participants undergoing living kidney donor transplantations
Measured: 24 months
Secondary outcomes (3)
Living Kidney Donor Evaluation Approved
Proportion of participants with ≥1 approved LDKT
Measured: 12 months
Living Kidney Donor Evaluation Started
Proportion of participants with at least one donor who started evaluation for living kidney donation
Measured: 12 months
Contact Living Donor Services
Proportion of participants with at least one donor who contacted living donor services
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jul 2022
- Study start18 Oct 2022
- Primary completionSep 2026 (estimated)
- Study completionSep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Living Donor Kidney TransplantationStudies of the same condition, open and under way.
- More trials run by University of AlbertaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Parallel block randomized control trial
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 66 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Alberta
- Sponsor type
- University, hospital or other
- Collaborators
- Alberta Innovates Health Solutions
- Responsible party
- Sponsor
- Investigators
- Dr. Shojai, Principal investigator, University of Alberta
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05459337
- Sponsor's protocol ID
- Pro00121297
- Acronym
- MuST AKT
- Status last verified
- Jan 2026
- First submitted
- 22 Jun 2022
- Last updated
- 7 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multidisciplinary Support to Access Living Donor Kidney Transplant (MuST AKT)
- ClinicalTrials.gov ID
- NCT05459337
- Acronym / sponsor ID
- MuST AKT / Pro00121297
- Conditions
- Living Donor Kidney Transplantation
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 66 participants (actual)
- Lead sponsor
- University of AlbertaUniversity, hospital or other
- Collaborators
- Alberta Innovates Health Solutions
- Study start
- 18 Oct 2022 (actual)
- Primary completion
- Sep 2026 (estimated)
- Study completion
- Sep 2026 (estimated)
- First posted
- 14 Jul 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
For people living with kidney failure, the two active treatment options are dialysis or kidney transplantation. Transplantation is optimal, and especially from a living donor - offering patients longer survival, a better quality of life, and cost savings for the health system when compared to dialysis. However, 20% of patients die on dialysis while waiting for a deceased donor organ. As the rate of kidney failure continues to rise, the gap between demand and supply of the organs for transplantation increases.
Compared to other provinces in Canada, the rate of living kidney donor transplantation is lower in Alberta, so it is essential that improvements are made to the process around living kidney donor transplantation, for better patient outcomes and care.
Our published evidence-based review on strategies to increase living kidney donation, found that for patients with kidney failure, the intervention with the greatest health impact was personalized support, provided by a multidisciplinary team, to inform and educate the patients' social network. A province-wide survey also confirmed that many patients with kidney failure are unable to find a living kidney donor and also find it difficult to approach potential donors due to lack of skills, supports, and resources.
The investigators have developed the Multidisciplinary Support To Access living donor Kidney Transplant (MuST AKT) intervention to support potential kidney transplant recipients find living donors through their social networks, and thereby increase the number of living kidney donor transplants in Alberta. The investigators will test the effectiveness of this intervention.
Detailed description
Living donor kidney transplantation (LDKT) is the optimal treatment for end-stage kidney disease patients, offering patients longer survival, a better quality of life, and cost savings for the health system when compared to dialysis. Outcome data shows that only 16% of Canadians on dialysis survive past 10 years, whereas up to 74% of Canadians with a kidney transplant have a functioning kidney after 10 years. The ideal treatment trajectory is to avoid dialysis entirely and receive a living donor transplant prior to dialysis (pre-emptive), which unfortunately only occurs in 10.5% of eligible patients.
Patients with kidney failure report barriers to LDKT, including navigating the system, addressing their concerns and fears, identifying and approaching potential living donors, keeping motivated, and then utilizing the ones unable to donate as advocates. To address these barriers and increase LDKT, the MuST AKT intervention has been developed. MuST AKT is designed to provide personalized support and enable potential kidney transplant recipients to communicate their story and desire for a LDKT with their personal and broader social networks.
A definitive Randomized Controlled Trial is proposed to test the effectiveness of the MuST AKT intervention to increase LDKT outcomes in a larger sample, before scaling to and implementing across Alberta.
Primary Objective:
The primary objective of this study is to examine the effectiveness of the MuST AKT intervention to increase living donor kidney transplantation outcomes.
Hypothesis:
The MuST AKT intervention will increase living donor kidney transplant outcomes compared to the control condition (standard care).
Additional Objectives:
The secondary objective is to evaluate patient outcome improvement by collecting Patient Reported Outcome Measures (PROMs) to assess the proportion of patients who find at least one potential living donor.
The tertiary objective is to evaluate patient experience by collecting i) qualitative interviews and ii) Patient Reported Experience Measures (PREMs) to determine whether this program would be recommended to other patients and to what extent this program helped find a potential living kidney donor.
The quaternary objective is to evaluate the feasibility of this program by assessing consent rate, attendance, adherence, drop-out, intervention fidelity, and cost-effectiveness.
Research Methods/Procedures:
This is a definitive parallel randomized controlled trial with a qualitative interview component. The intervention condition will receive a multidisciplinary, tailored person-centered intervention over three months (MuST AKT program), and the control condition will receive the current standard of care (social worker assessment).
Patients who have been referred for kidney transplantation assessment in Edmonton will be contacted during a standard care kidney transplant education session or over the telephone if the education has been completed. Consenting participants meeting the eligibility requirements will be contacted via telephone by a member of the research team to confirm their enrollment and complete a baseline questionnaire to assess socio-demographics and PREMs. Then participants will be randomized to either the intervention or control condition, using predetermined randomly-generated (by Stata MP 15·1) permuted blocks of 4 and 6. Assignment to condition will be concealed by the database up until the point of assignment. All group and individual sessions will be held either virtually or in-person, at the participants discretion, as long as there are no public health (e.g., COVID-19) restrictions that would prevent in-person visits. If there are public health restrictions that prevent in-person visits, the sessions will be held virtually. Consent rate, attendance, adherence, drop-out, and intervention fidelity will be tracked during enrollment and throughout the duration of the intervention. Upon completion of the intervention (or usual care), participants will complete a post-intervention questionnaire to assess PREMs. Participants in the MuST AKT intervention condition who complete the intervention sessions will be contacted to participate in a semi-structured qualitative interview over the telephone (approximately 45 minutes) within two weeks of their last session. Participants who complete the MuST AKT intervention condition but have not had a potential donor come forward after 12 months of the last session will be contacted to complete a semi-structured interview over the telephone (approximately 20 minutes) to explore factors contributing to their lack of success. Kidney transplant status will be tracked for a period of 24 months post-intervention.
The cost-effectiveness of the intervention will be evaluated after participant data collection is complete (24 months), and values obtained from study records (cost of developing and delivering intervention) and previously published estimates of living donor work-ups and transplantation costs, and cost-savings due to forgoing of alternative therapies (i.e., dialysis).
Intervention Condition: MuST AKT is a multidisciplinary, tailored person-centered intervention aimed to support participants identification of potential donors and communication with their social network. An introductory session will be followed by three sessions (all one-on-one) and a final session 4 with participants family and friends (potential donors and advocates) identified in session 1. The introductory session will be approximately 60 minutes and the remaining intervention sessions will be approximately 90 minutes. Sessions will be facilitated by a trained licensed social worker, a coordinator, or a media expert, with extra training in kidney disease, transplantation, living kidney donation, counselling and interviewing, and patient confidentiality.
Usual care (control condition): In the control condition, participants will go through the current standard of care, which is a social worker assessment. If the intervention is successful in the definitive RCT and approved by Alberta Health Services as the 'new standard of care', people in control condition will be contacted and given the option to participate in the MuST AKT intervention.
Additional Interviews with separate informed consent procedures: Friends and family members of participants taking part in session 4 will be invited to participate in a sub-study, which aims to explore their experiences of group session 4. Those expressing interest will be contacted by a qualitative researcher via telephone, and following informed consent, will participate in a semi-structured interview lasting approximately 20 minutes.
Plan for Data Analysis:
Quantitative: All analyses will be completed in Stata/MP 17.0 (www.stata.com), using an intention-to-treat approach. Fisher's exact tests (for dichotomous outcomes), and t-tests or Wilcoxon rank-sum tests (for continuous outcomes data), will be used as appropriate. Unadjusted proportions, means or medians and their differences along with 95% confidence intervals will be reported. P <0.05 will be considered statistically significant for all quantitative outcomes. Residual, leverage and influence diagnostics will be examined.
Our primary analyses (which includes primary and secondary outcomes) will pool data from both the pilot and the current trials. In secondary analyses, we will generate within trial results to investigate potential heterogeneity of intervention delivery.
Qualitative: Data will be analyzed in NVivo-12 by experienced qualitative researchers independent of the study, using deductive thematic analysis. A coding framework will be established based on the interview guides and updated to include additional themes that emerge from the data. The coding framework will be validated by two coders, any disagreements will be resolved through discussion.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (investigator)
- Number of arms
- 2
- Model description
- Parallel block randomized control trial
| Arm | Type | Receives |
|---|---|---|
| Intervention | Experimental | Behavioral: MuST AKTThis arm will receive the MuST AKT intervention, which is a multidisciplinary, tailored person-centered behavioural intervention designed to "help and enable" the potential kidney transplant recipients to achieve what is required to receive a living donor kidney transplantation. |
| Usual Care (control) | No intervention | –In the usual care (control) condition, participants will go through the current standard of care, which is a social worker assessment. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- English speaking
- No obvious contraindication to kidney transplantation
- Successfully completed 'introduction to kidney transplant' module
Key exclusion criteria (5 listed)
- Potential Living Kidney Donor identified
- Previously received organ transplant
- Candidate for multi-organ transplant
- Stanford Integrated Psychosocial Assessment for Transplant (SIPAT) Score >20
- Rapid Estimate of Adult Literacy in Medicine (REALM-66) score <19(illiterate in English)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MuST AKTA behavioural intervention designed to help participants identify and communicate with their social network about living kidney donation. | Behavioural | Intervention |
Primary outcome
Living Kidney Donor Transplantation
Time frame: 24 months
Proportion of participants undergoing living kidney donor transplantations
3 secondary outcomes
Living Kidney Donor Evaluation Approved
Time frame: 12 months
Living Kidney Donor Evaluation Started
Time frame: 12 months
Contact Living Donor Services
Time frame: 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Jan 2026.
- Individual participant dataSharing planned: No
Related trials for Living Donor Kidney Transplantation
Not yet recruitingPhase 1
ECP-DL Cell Infusion for Induction in Living Donor Kidney (LDK) Transplants
Kidney Transplant Failure and Rejection, Kidney Transplant; Complications
Not yet recruiting
Prophylactic Norepinephrine for Prevention of Acute Kidney Injury in Living-Donor Liver Transplantation
Noradrenaline
Not yet recruiting
Technology-enabled Social Network Intervention to Increase Live Donor Kidney Transplantation
End-Stage Renal Disease, Chronic Kidney Diseases
Enrolling by invitationPhase 4
Enhanced Recovery After Surgery (ERAS) in Live Donor Kidney Transplant Recipients
Postoperative Pain
Active, not recruitingPhase 1/2
Cell Therapy for Immunomodulation in Kidney Transplantation
Kidney Transplantation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dr. Shojai principal investigator
University of Alberta
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing MuST AKT in people with Living Donor Kidney Transplantation, run by University of Alberta at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 7 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Living Kidney Donor Transplantation (time frame: 24 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jan 2026.